Directorio

In this study, people will take capsules that contain either the study drug, called vamifeport, or a placebo, which looks the same but has no medicine. The study lasts about fourteen months and has around fifteen in person visits. At these visits, people will have blood tests, heart tests called ECGs, MRI scans, and questionnaires. If someone gets vamifeport, they will take it twice a day in one of two dose groups. One group takes 90 milligrams twice a day, which is one capsule in the morning and one in the evening. The other group takes 270 milligrams twice a day, which is three capsules in the morning and three in the evening. If someone gets a placebo, they will also take either one capsule twice a day or three capsules twice a day, depending on their group.

We are doing this study to find out if an investigational drug called tocilizumab (the study drug) will lead to better outcomes after lung transplantation when it is combined with standard anti-rejection medicines.

We are doing this research to learn more about whether taking a blood thinner, along with medications that prevent blood clots, improve outcomes in patients who develop atrial fibrillation (irregular heartbeat) after coronary artery bypass grafting surgery.

We are doing this study to find out if an investigational drug called CA-4948 is a safe and effective option for people with PCNSL. We want to know how well it works when it is combined with a drug called ibrutinib, which is commonly used to treat PCNSL.

This study includes up to three sessions that take about 5 to 6 hours in total. These sessions can happen all on the same day or be spread out over two months. People who join will first go through a screening and sign consent forms. They will then have an MRI scan and do head-tracking tasks using two different systems - one regular and one that uses computer vision. The study also includes finding the TMS motor threshold, which means using a small magnetic pulse to make a finger twitch. Participants will also receive sham TMS, which feels like real TMS but does not affect the brain, over a part of the brain called the prefrontal cortex. This study is testing a new, non-invasive system that does not need tracking tools on the head. It is made for research and does not involve any medicine or random group assignments.